Gil, Miguel J <br/><br/>
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).  [electronic resource] 

 -  Anti-cancer drugs  Jul 2012 
 - 659-65 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1473-5741 
<br/><br/><label>Standard No.: </label>10.1097/CAD.0b013e3283534d3e  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Camptothecin--administration & dosage<br/>Central Nervous System Neoplasms--drug therapy<br/>Compassionate Use Trials<br/>Dacarbazine--analogs & derivatives<br/>Disease Progression<br/>Glioma--drug therapy<br/>Humans<br/>Irinotecan<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Retrospective Studies<br/>Temozolomide<br/>Treatment Outcome